Triple-threat treatment aims to make inoperable lung cancer removable
NCT ID NCT07309952
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase II trial tests whether giving a short course of radiation, followed by two cycles of immunotherapy (sintilimab) plus chemotherapy, can shrink advanced lung cancer that has spread to lymph nodes on the opposite side of the chest. The goal is to make the cancer operable and improve long-term outcomes. The study enrolls 28 adults aged 18–75 with previously untreated stage IIIB or IIIC non-small cell lung cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sintilimab (immunotherapy), paclitaxel or nab-paclitaxel (chemotherapy), and stereotactic body radiotherapy (radiation)
What this could lead to
If successful, this approach could help shrink tumors enough to allow surgery in patients with advanced lung cancer, potentially improving survival and reducing recurrence.
What could go wrong
This is a small, early-phase trial with only 28 participants, so results may not apply to everyone. The combination of radiation, immunotherapy, and chemotherapy can cause significant side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••